CClinicalTrials.gg
WithdrawnNCT00484172Updated Jan 6, 2021

Genomic Search for Childhood Obesity Genes-A Pilot Study

An observational study in Obesity, sponsored by Children's Mercy Hospital Kansas City. Withdrawn at 1 site in United States. Open to participants aged 2 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Children's Mercy Hospital Kansas City · Observational

Why this study was withdrawn
Study Withdrawn due to Investigator leaving
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
0
Ages
2 Years to 8 Years
Sex
All
01

Study summary

The purpose of this study is to screen a pediatric population (ages 2-8) for genes associated with childhood obesity.

Read the detailed description

The incidence of childhood obesity has been growing at an epidemic rate for the past several years, in part due to the lack of understanding of mechanisms at a molecular level. This study will screen a healthy general pediatric population age 2 to 8 for potential genes associated with childhood obesity using whole genomic gene arrays. Patients with BMI values equal to or greater than the 85th percentile will be compared to patients with a BMI below or equal to the 15th percentile. The INSIG2 gene will be specifically studied because of its identification in several populations of obese subjects. The differences in gene expression of the 2 groups will then be used to identify new genes for investigation in childhood obesity.

02

Conditions studied

  • Obesity

Keywords

  • Obesity
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

Browse Obesity studies →

Lead sponsor

Children's Mercy Hospital Kansas City is the lead sponsor of 209 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children aged 2-8 years old

Inclusion criteria

  • Ages 2-8, predominately Caucasian to minimize population stratification

Exclusion criteria

Exclusion Criteria:

  • Chronic diseases (diabetes, cancer, etc) and known syndromes
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Interventions

  • Procedureblood draws
06

Study locations

1 site
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00484172
Lead sponsor
Children's Mercy Hospital Kansas City
Responsible party
Sponsor
First posted
Jun 8, 2007
Start date
Jun 2007
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Jan 6, 2021

Study contacts

Merlin G Butler, M.D., Ph.D.
principal investigator · Children's Mercy Hospital Kansas City

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion